Introduction:
- Follicle-stimulating hormone (FSH) has been indicated in the development and progression of prostate cancer.
- Coupled with testosterone suppression to castration levels, FSH suppression may delay disease progression, and improve prognosis.
- Degarelix, a gonadotropin-releasing hormone (GnRH) antagonist, has been associated with rapid and profound testosterone and FSH suppression along with prostate specific antigen (PSA) suppression.
- Here we present the factors predicting the FSH suppression including ′on treatment′ PSA suppression from an already published study.
Click Image to Enlarge